Skip to main content

Table 2 Laboratory parameters of mCRPC studied patients before and after 3 cycles of PSMA-RLT at 4 weekly intervals

From: Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks

ParametersBefore therapyAfter therapyP value
*PSA μg/L66 (1.0–4890)19.8 (0.7–4563)< 0.001
Hemoglobin g/dL (mean ± SD)11.7 ± 1.911.4 ± 1.9NS
Thrombocytes g/L (mean ± SD)236 ± 71193 ± 67< 0.001
*Leucocytes g/L6.5 (2.9–13.7)4.8 (1.5–12.3)< 0.001
*Creatinine mg/dL0.9 (0.6–1.6)0.86 (0.6–1.8)NS
*Alkaline phosphatase U/L (mean ± SD)66 (27–469)68 (27–580)NS
*LDH (mean ± SD) U/L189 (136–620)197 (125–323)NS
  1. *Data with no Gaussian distribution, presented in median (range) and log10-transformd for analysis. NS not significant. P < 0.05 = statically significant